Related Experiment Video
Updated: Aug 6, 2026

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry
Published on: December 26, 2019
Metabolic Profiling of Circulating and Tumour-Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With
Hugo Brouque1,2, Kareem Madhy1,2, Stephane Mouret3
1Institute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.
Abstract:
Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour-infiltrating CD4+ and CD8+ T cells of melanoma patients at a single-cell level using the SCENITH method and targeted metabolomics. Circulating and tumour-infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T-cell features and metabolic patterns. Targeted metabolomics within sorted CD4+/CD8+ T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour-infiltrating CD4+ T cells, and in glycerolipid DG(16:0/16:0) within CD8+ T cells in blood and tumour. We further outlined a metabolic-checkpoint-based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour-infiltrating T cells (LIPA, DGKA, GLUL, SLC38A1, SLC7A7, GCH1) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti-tumour responses and improve clinical success.